Wechselwirkungen · Duavive
DUAVIVE 0.45 mg/20 mg modified-release tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-125222 · Präparat HOS-096029
The metabolism of oestrogens may be increased by concomitant use of substances known to induce drug-metabolising enzymes, such as anticonvulsants (e.g., phenobarbital, phenytoin, carbamazepine) and anti-infectives (e.g., rifampicin, rifabutin, nevirapine, efavirenz). Ritonavir and nelfinavir, although known as strong inhibitors, by contrast exhibit inducing properties when used concomitantly with steroid hormones. Herbal preparations containing St John’s wort (Hypericum perforatum) may induce the metabolism of oestrogens. Clinically, an increased metabolism of oestrogens may lead to decreased effect and changes in the uterine bleeding profile.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nelfinavir (HOS-084520) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) lead (HOS-085592) efavirenz (HOS-087947) nevirapine (HOS-088064) ritonavir (HOS-084521) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-06T02:00:00Z · SHA-256 cebc18aeeaa7e87d26ff41a36f1789bee3f7e1eaa839d2f6fdebebc62c1ef614 · Passage 4a99433b964f0cd0cd7d5317ff115a711319519a8c0c69338ef1236b324782c3 · Zeichen 660–1311 im Abschnitt